期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氯吡格雷抵抗基因多态性的研究进展 被引量：5

Review on Clopidogrel Resistant Genetic Polymorphisms
下载PDF
导出
摘要 氯吡格雷是目前广泛应用的抗血小板药物,其对血小板的抑制具有个体差异性,部分患者在服用常规剂量氯吡格雷后存在抵抗现象而发生临床血栓事件。目前氯吡格雷抵抗的机制尚不十分清楚,基因多态性被认为是其中一个重要的原因。现就氯吡格雷抵抗基因多态性作一综述。 Clopidogrel is a widely used antiplatelet aggregation drug. However, clopidogrel-induced platelet inhibition is patient-spe- cific. The presence of clopidogrel resistance indicates that cardiovascular events can still occur in patients taking standard dose clopidogrel therapy. At present the clopidogrel resistance mechanism still is not very clear, genetic polymorphism is considered to be one of the important reasons. This article discusses currently available evidence surrounding the genetic polymorphisms of clopidogrel resistance.
作者 张晶 马依彤 穆巴拉克
机构地区 新疆医科大学第一附属医院心脏中心 新疆医科大学药学院
出处 《心血管病学进展》 CAS 2012年第1期51-54,共4页 Advances in Cardiovascular Diseases
关键词 氯吡格雷抵抗 基因多态性 clopidogrel resistance polymorphisms
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献23

  • 1Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in tle two oxidative steps in the bioactivation of clopidogrel to its phamacologicall active metabolite[J]. Drug Metab Dispos, 2010, 38:92-99.
  • 2Wiviott SD, Braunw'ald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 thai: a subanalysis of a randomised trial[ J]. Lancet, 2008,371 ( 9621 ) : 1353-1363.
  • 3Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation [ J ]. N Engl J Med, 2005,352(12) :1179-1189.
  • 4Sugunaraj JP, Palaniswamy C, Selvaraj DR, et al. Clopidogrel resistance [ J ]. Am J Ther, 2010,17(2) :210-215.
  • 5Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel : a review of the evidence[J]. J Am Call Cardiol, 2005,45(8) :1157-1164.
  • 6Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity [ J ]. Circulation, 2003,107 ( 23 ) :2908-2913.
  • 7Guisset T, Frere C, Quilici J, et al. Role of the T744c polymorphism of tile P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome [ J ]. Thromb Res, 2007,120 (6) : 893 -899.
  • 8Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoproteln phosphorylation in dex decrease rate of major adverse prospective study[J]. J Am Coil Cardiol, 2008,51 (14) : 1404-1411.
  • 9Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphie CYP3A5 expression[JJ. Nat Genet, 2001,27(4) :383-391.
  • 10Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polym idogrel[ J]. CMAJ, 2006,14-7 (12) : 1715-1722.

同被引文献54

  • 1Tantry U S,Bliden K P,Guibel P A. Resistance to antipatelet drugs:current status and future research[J].{H}EXPERT OPINION ON PHARMACOTHERAPY,2005,(12):2027.
  • 2Sebatine M S,Cannon C P,Gibson C M. Addition of clopidogrel to aspirin and flbrinolytic therapy formyocardial infarctionwith ST-segmentelevation[J].{H}New England Journal of Medicine,2005,(12):1179.
  • 3Sugunataj M S,Palaniswamy C,Selvaraj D R. Clopidogrel resistance[J].{H}American Journal of Therapeutics,2010,(02):210.
  • 4Bouman H J,Schomig E,Werkum J W van. Paraoxonase-1 is a major determinant of clopidogrel efficacy[J].{H}Nature Medicine,2011,(01):110.
  • 5Massberg S,Svchulz C,Gawaz M. Role of paltelets in the pathophysiology of acute coronary syndrome[J].Semin Vase Med,2003,(02):147.
  • 6Guthikonda S,lev E I,Kleiman N S. Resistance to antiplatelet therapy[J].{H}Current Cardiology Report,2005,(04):242.
  • 7Nguyen T A,Diodati J G,Pharand C. Resistance to clopidogrel:a review of the evidence[J].{H}Journal of the America College of Cardiology,2005,(08):1157.
  • 8Osmancik P,Paulu P,Tousek P. High leukocyte count and interleukin 10 predit high on-treatment-platelet-reactivity in patients treated with clopidogrel[J].{H}Journal of Thrombosis and Thrombolysis,2012,(04):349.
  • 9Simon T,Verstuyft C,Mary-Krause M. Genetic determinants of response to clopidogrel and cardiovascular events[J].{H}New England Journal of Medicine,2009,(04):363.
  • 10Mega J L,Close S L,Wiviott S D. Cytochrome P-450 polymorphisms and response to clopidogrel[J].{H}New England Journal of Medicine,2009,(04):354.

引证文献5

二级引证文献13

心血管病学进展
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部